Search

"Among the most important innovations that will be available in the near future are anti-obesity pills and the triple agonist retatrutide." Professor Andrea Fabbri, a professor of Endocrinology at the University of Tor Vergata in Rome, explains: "Among the most important innovations that will be available in the near future are anti-obesity pills and the triple agonist retatrutide." #obesità #incretine #salute (translated)

The author described retatrutide as a breakthrough in obesity treatment, saying that after 80 weeks, participants had lost an average of 25% of their weight, with less knee pain and fewer sleep apnea episodes. At a dose of 12 mg per week, weight loss was 28.3%, and 45.3% of participants lost at least 30% of their weight, the author wrote.

Už se opakuji. Retatrutide, neregistrovaný lék podobný Mounjaru. Lze koupit na internetu. Pacientka to udělala a měla po aplikaci bouřlivou alergickou reakci. Nedělejte to. A mimochodem, platila 6 tisíc... Nechápu. #zdraví #léky #bezpečnost

Na internetu si lze objednat experimentální lék, vyrobený v Číně. Koupíš si prášek, doma si to umixuješ a potom apliuješ injekčně. Je to silnější než Mounjaro. Stačí tam napsat, že je to “pouze pro výzkum”. Retatrutide.... Jsou věci, které nepochopím. To se ti lidé nebojí? #experimentálnílék #zdraví #internet

Los fármacos antiobesidad como el GLP-1, Ozempic, Wegovy y el recientemente investigado retatrutide, no solo ayudan en la pérdida de peso, sino que también aportan beneficios significativos en el corazón, riñones y hígado, actuando en múltiples sistemas del cuerpo gracias a su larga duración en el organismo y su capacidad de estimular la liberación de insulina. #GLP1 #Obesidad #FármacosAntiadiposos

Das experimentelle Abnehmmittel Retatrutide von Eli Lilly erzielte in einer Studie einen durchschnittlichen Gewichtsverlust von über 28 Prozent bei fettleibigen Patienten und könnte bald für eine behördliche Zulassung beantragt werden, nachdem es als das stärkste Präparat zur Gewichtsreduktion gilt, das gleichzeitig drei Hormonrezeptoren aktiviert. #Gewichtsverlust #Abnehmmittel #Gesundheit

Retatrutide is an investigational once-weekly injectable medication that targets three metabolic receptors—GLP-1, GIP, and glucagon—to suppress appetite, optimize insulin secretion, and increase energy expenditure. Clinical trials show it drives substantial weight loss. That’s #Retatrutide #WeightLoss #DiabetesManagement #Thetweetdoesnotmentionanyspecificcountries.Therefore #therearenocountrycodestoreturn.

Retatrutide is an experimental triple-hormone (GLP-1, GIP, and glucagon) agonist that strongly suppresses appetite. Because it dramatically reduces hunger and promotes rapid weight loss, medical experts warn that stopping eating entirely can lead to dangerous muscle loss, #Retatrutide #WeightLoss #HungerSuppression #Nospecificcountrycodesarementionedinthetweetprovided.

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz explores how the popularity of GLP-1 drugs, like Wegovy and retatrutide, is influenced not only by their effectiveness in weight loss but also by the cultural obsession with wellness and social media that promotes biohacking and easy access to such substances. #HealthInnovation #Pharmaceuticals #WellnessCulture #CN

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz explores how the rise of GLP-1 drugs, such as Wegovy and retatrutide, reflects not only their efficacy as weight loss solutions but also the impact of social media and a wellness-obsessed culture, leading to a surge in online interest and experimentation with these substances amidst concerns about safety and purity. #Health #Wellness #Pharmaceuticals #CN

In a discussion on "The Ezra Klein Show," health journalist Julia Belluz analyzes the rise of GLP-1 drugs like Wegovy and retatrutide, exploring how their popularity is fueled not just by their weight-loss effects but by the influence of social media culture and a wellness-obsessed society that encourages biohacking and unregulated drug use. #Health #Wellness #Pharmaceuticals #CN